Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure

Demetrios Georgiou, Yu Chen, Sheila Appadoo, Romualdo Belardinelli, Richard Greene, Michael K. Parides, Sherry Glied

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The purpose of this study is to perform a cost-effectiveness analysis of long-term moderate exercise training (ET) in patients with stable chronic heart failure. In particular, the study focuses on the survival analysis and cost savings from the reduction in the hospitalization rate in the exercise group. In the past 10 years, ET has been shown to be beneficial for patients with stable class II and III heart failure in many randomized clinical trials. However, the cost-effectiveness of a long-term ET program has not been addressed for outcomes related to morbidity/mortality end points or health care utilization. We examined the cost-effectiveness of a 14-month long-term training in patients with stable chronic heart failure. The estimated increment cost for the training group, $3,227/patient, was calculated by subtracting the averted hospitalization cost, $1,336/patient, from the cost of ET and wage lost due to ET, estimated at $4,563/patient. For patients receiving ET, the estimated increment in life expectancy was 1.82 years/person in a time period of 15.5 years, compared with patients in the control group. The cost-effectiveness ratio for long-term ET in patients with stable heart failure was thus determined at $1,773/life-year saved, at a 3% discount rate. Long-term ET in patients with stable chronic heart failure is cost-effective and prolongs survival by an additional 1.82 years at a low cost of $1,773 per/life-year saved.

Original languageEnglish (US)
Pages (from-to)984-988
Number of pages5
JournalAmerican Journal of Cardiology
Volume87
Issue number8
DOIs
StatePublished - Apr 15 2001
Externally publishedYes

Fingerprint

Cost-Benefit Analysis
Heart Failure
Exercise
Costs and Cost Analysis
Hospitalization
Point-of-Care Systems
Patient Acceptance of Health Care
Cost Savings
Salaries and Fringe Benefits
Survival Analysis
Life Expectancy
Randomized Controlled Trials
Morbidity
Education
Control Groups
Survival
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. / Georgiou, Demetrios; Chen, Yu; Appadoo, Sheila; Belardinelli, Romualdo; Greene, Richard; Parides, Michael K.; Glied, Sherry.

In: American Journal of Cardiology, Vol. 87, No. 8, 15.04.2001, p. 984-988.

Research output: Contribution to journalArticle

Georgiou, Demetrios ; Chen, Yu ; Appadoo, Sheila ; Belardinelli, Romualdo ; Greene, Richard ; Parides, Michael K. ; Glied, Sherry. / Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. In: American Journal of Cardiology. 2001 ; Vol. 87, No. 8. pp. 984-988.
@article{d6f25419d53e423d860bca02ea0d0842,
title = "Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure",
abstract = "The purpose of this study is to perform a cost-effectiveness analysis of long-term moderate exercise training (ET) in patients with stable chronic heart failure. In particular, the study focuses on the survival analysis and cost savings from the reduction in the hospitalization rate in the exercise group. In the past 10 years, ET has been shown to be beneficial for patients with stable class II and III heart failure in many randomized clinical trials. However, the cost-effectiveness of a long-term ET program has not been addressed for outcomes related to morbidity/mortality end points or health care utilization. We examined the cost-effectiveness of a 14-month long-term training in patients with stable chronic heart failure. The estimated increment cost for the training group, $3,227/patient, was calculated by subtracting the averted hospitalization cost, $1,336/patient, from the cost of ET and wage lost due to ET, estimated at $4,563/patient. For patients receiving ET, the estimated increment in life expectancy was 1.82 years/person in a time period of 15.5 years, compared with patients in the control group. The cost-effectiveness ratio for long-term ET in patients with stable heart failure was thus determined at $1,773/life-year saved, at a 3{\%} discount rate. Long-term ET in patients with stable chronic heart failure is cost-effective and prolongs survival by an additional 1.82 years at a low cost of $1,773 per/life-year saved.",
author = "Demetrios Georgiou and Yu Chen and Sheila Appadoo and Romualdo Belardinelli and Richard Greene and Parides, {Michael K.} and Sherry Glied",
year = "2001",
month = "4",
day = "15",
doi = "10.1016/S0002-9149(01)01434-5",
language = "English (US)",
volume = "87",
pages = "984--988",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure

AU - Georgiou, Demetrios

AU - Chen, Yu

AU - Appadoo, Sheila

AU - Belardinelli, Romualdo

AU - Greene, Richard

AU - Parides, Michael K.

AU - Glied, Sherry

PY - 2001/4/15

Y1 - 2001/4/15

N2 - The purpose of this study is to perform a cost-effectiveness analysis of long-term moderate exercise training (ET) in patients with stable chronic heart failure. In particular, the study focuses on the survival analysis and cost savings from the reduction in the hospitalization rate in the exercise group. In the past 10 years, ET has been shown to be beneficial for patients with stable class II and III heart failure in many randomized clinical trials. However, the cost-effectiveness of a long-term ET program has not been addressed for outcomes related to morbidity/mortality end points or health care utilization. We examined the cost-effectiveness of a 14-month long-term training in patients with stable chronic heart failure. The estimated increment cost for the training group, $3,227/patient, was calculated by subtracting the averted hospitalization cost, $1,336/patient, from the cost of ET and wage lost due to ET, estimated at $4,563/patient. For patients receiving ET, the estimated increment in life expectancy was 1.82 years/person in a time period of 15.5 years, compared with patients in the control group. The cost-effectiveness ratio for long-term ET in patients with stable heart failure was thus determined at $1,773/life-year saved, at a 3% discount rate. Long-term ET in patients with stable chronic heart failure is cost-effective and prolongs survival by an additional 1.82 years at a low cost of $1,773 per/life-year saved.

AB - The purpose of this study is to perform a cost-effectiveness analysis of long-term moderate exercise training (ET) in patients with stable chronic heart failure. In particular, the study focuses on the survival analysis and cost savings from the reduction in the hospitalization rate in the exercise group. In the past 10 years, ET has been shown to be beneficial for patients with stable class II and III heart failure in many randomized clinical trials. However, the cost-effectiveness of a long-term ET program has not been addressed for outcomes related to morbidity/mortality end points or health care utilization. We examined the cost-effectiveness of a 14-month long-term training in patients with stable chronic heart failure. The estimated increment cost for the training group, $3,227/patient, was calculated by subtracting the averted hospitalization cost, $1,336/patient, from the cost of ET and wage lost due to ET, estimated at $4,563/patient. For patients receiving ET, the estimated increment in life expectancy was 1.82 years/person in a time period of 15.5 years, compared with patients in the control group. The cost-effectiveness ratio for long-term ET in patients with stable heart failure was thus determined at $1,773/life-year saved, at a 3% discount rate. Long-term ET in patients with stable chronic heart failure is cost-effective and prolongs survival by an additional 1.82 years at a low cost of $1,773 per/life-year saved.

UR - http://www.scopus.com/inward/record.url?scp=0035871463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035871463&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(01)01434-5

DO - 10.1016/S0002-9149(01)01434-5

M3 - Article

VL - 87

SP - 984

EP - 988

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8

ER -